The Camargo Way Case Studies Post-Marketing Nonclinical Case Study

Rapid Nonclinical Planning and Coordination Keep Post-Marketing Requirements on Track

Challenge: A sponsor needed support completing post-marketing requirements under a tight timeline.


Leveraging the 505(b)(2) pathway, a biotech company achieved paper NDA approval for a parenteral acute use drug. While no new nonclinical studies were required for this approval, the FDA required a complete DART package and in vivo genotoxicity study within a short timeframe to meet Phase 4 post-marketing requirements.



Camargo selected CROs to run the multi-species genotoxicity program, within the FDA’s agreed upon timelines. In coordination with the CRO, Camargo drafted the protocols and submitted them to the FDA for concurrence prior to initiating the studies. Due to significant delays with FDA protocol review and approval, Camargo worked with the CRO to further expedite the studies and still meet the original Phase 4 post-marketing timelines. Camargo served as the sponsor’s study monitor and coordinated all day-to-day activities, communications with the study director and principal investigators, data reviews, on-site study monitoring, draft report review, and report finalization.



Under Camargo’s oversight, all final reports were completed in accordance with the Phase 4 commitments.

Page 4 of 4

Get Our Diverse Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our Solutions or Contact Us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights